



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Date Submitted: June 8, 2009

(use as many sheets as necessary)

Sheet 1 of 25

Complete if Known

Application Number	09/506,011
Filing Date	02/17/2000
First Named Inventor	John Cooper Cox
Art Unit	1648
Examiner Name	Emily M. Le
Attorney Docket Number	017227-0155

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A1	US 2006/0287263	12-21-2006	Davis et al.	
	A2	US 2009/0017021 A1	01-15-2009	Davis et al.	
	A3	US 2007/0190072	08-16-2007	Cebon et al.	
	A4	US 2006/0210555	09-21-2006	Kensil et al.	
	A5	US 5,897,873	04-13-1999	Popescu	
	A6	US 2003/0118635 A1	06-26-2003	Dalsgaard et al.	
	A7	US 2003/0139364 A1	07-24-2003	Kreig et al.	
	A8	US 2003/0191079 A1	10-09-2003	Kreig et al.	
	A9	US 2004/0038922 A1	02-26-2004	Haensler et al.	
	A10	US 2004/0106568 A1	06-03-2004	Krieg et al.	
	A11	US 2004/0247662 A1	12-09-2004	Dow et al.	
	A12	US 2004/0266719 A1	12-30-2004	McCluskie et al.	
	A13	US 2005/0013812 A1	01-20-2005	Dow et al.	
	A14	US 2005/0031638 A1	02-10-2005	Dalemans et al.	
	A15	US 2005/0037985 A1	02-17-2005	Krieg et al.	
	A16	US 2005/0079152 A1	04-14-2005	Bot et al.	
	A17	US 2005/0101554 A1	05-12-2005	Krieg et al.	
	A18	US 2005/0119273 A1	06-02-2005	Lipford et al.	
	A19	US 2005/0130911 A1	06-19-2005	Uhlmann et al.	
	A20	US 2005/0215501 A1	09-29-2005	Lipford et al.	
	A21	US 2006/0003962 A1	01-05-2006	Ahluwalia et al.	
	A22	US 2006/0019923 A1	01-26-2006	Davis et al.	
	A23	US 2006/0058251 A1	03-16-2006	Krieg et al.	
	A24	US 2006/0172966 A1	08-03-2006	Lipford et al.	
	A25	US 2006/0188913 A1	08-24-2006	Krieg et al.	
	A26	US 2006/0229271 A1	10-12-2006	Krieg et al.	
	A27	US 2006/0246035 A1	11-02-2006	Ahluwalia et al.	
	A28	US 2007/0232622 A1	10-04-2007	Lipford et al.	
	A29	US 4,578,269	03-25-1986	Morein	
	A30	US 4,981,684	01-01-1991	MacKenzie et al.	
	A31	US 5,178,860	01-12-1993	MacKenzie et al.	
	A32	US 5,284,656	02-08-1994	Platz et al.	
	A33	US 5,451,569	09-19-1995	Wong et al.	
	A34	US 5,679,354	10-21-1997	Morein et al.	
	A35	US 6,558,670 B1	05-06-2003	Friede et al.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: June 8, 2009 <i>(use as many sheets as necessary)</i>			Application Number	09/506,011	
			Filing Date	02/17/2000	
			First Named Inventor	John Cooper Cox	
			Art Unit	1648	
			Examiner Name	Emily M. Le	
Sheet	2	of	25	Attorney Docket Number	017227-0155

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A36	US 6,610,308 B1	08-26-2003	Haensler	
	A37	US 6,027,732	02-22-2000	Morein et al.	
	A38	US 6,339,068 B1	01-15-2002	Krieg et al.	
	A39	US 5,057,540	10-15-1991	Kensil et al.	
	A40	US 5,273,965	12-28-1993	Kensil et al.	
	A41	US 5,443,829	08-22-1995	Kensil et al.	
	A42	US 5,583,112	12-10-1996	Kensil et al.	
	A43	US 5,650,398	07-22-1997	Kensil et al.	
	A44	US 5,977,081	11-02-1999	Marciani	
	A45	US 6,080,725	06-27-2000	Marciani	
	A46	US 6,231,859 B1	05-15-2001	Kensil	
	A47	US 7,049,302 B1	05-23-2006	Kensil	
	A48	US 6,352,697 B1	03-05-2002	Cox et al.	
	A49	US 6,881,821 B2	04-2005	Simmonds et al.	
	A50	US 7,198,892 B2	04-2007	Simmonds et al.	
	A51	US 5,663,153	09-02-1997	Hutcherson et al.	
	A52	US 5,723,335	03-03-1998	Hutcherson et al.	
	A53	US 5,780,448	07-14-1998	Davis	
	A54	US 6,194,388 B1	02-27-2001	Krieg et al.	
	A55	US 6,207,646 B1	03-27-2001	Krieg et al.	
	A56	US 6,214,806 B1	04-10-2001	Krieg et al.	
	A57	US 6,218,371 B1	04-17-2001	Krieg et al.	
	A58	US 6,221,882	04-24-2001	Macfarlane	
	A59	US 6,239,116 B1	05-29-2001	Krieg et al.	
	A60	US 6,339,630	06-04-2002	Macfarlane	
	A61	US 6,406,705 B1	06-18-2002	Davis et al.	
	A62	US 6,429,199 B1	08-06-2002	Krieg et al.	
	A63	US 6,479,504	11-12-2002	Macfarlane et al.	
	A64	US 6,521,637	02-18-2003	Macfarlane	
	A65	US 6,610,661 B1	08-26-2003	Carson et al.	
	A66	US 6,653,292 B1	11-25-2003	Krieg et al.	
	A67	US 6,727,230 B1	04-27-2004	Hutcherson et al.	
	A68	US 6,821,957 B1	11-23-2004	Krieg et al.	
	A69	US 6,835,395 B1	12-28-2004	Semple et al.	
	A70	US 6,943,240	09-13-2005	Bauer et al.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: June 8, 2009 <i>(use as many sheets as necessary)</i>		Application Number	09/506,011
		Filing Date	02/17/2000
		First Named Inventor	John Cooper Cox
		Art Unit	1648
		Examiner Name	Emily M. Le
Sheet	3	of	25
		Attorney Docket Number	017227-0155

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A71	US 6,949,520	09-27-2005	Hartmann et al.	
	A72	US 7,001,890	02-26-2006	Wagner et al.	
	A73	2001-0044416 A1	11-12-2001	McCluskie et al.	
	A74	2002-0065236 A1	05-30-2002	Yew et al.	
	A75	2002-0091097 A1	07-11-2002	Bratzler et al.	
	A76	2002-0164341 A1	11-07-2002	Davis et al.	
	A77	2002-0192184 A1	12-19-2002	Carpentier et al.	
	A78	2003-0026801 A1	02-06-2003	Weiner et al.	
	A79	2003-0050261 A1	03-13-2003	Krieg et al.	
	A80	2003-0050268 A1	03-13-2003	Krieg et al.	
	A81	2003-0091599 A1	05-15-2003	Davis et al.	
	A82	2003-0100527 A1	05-29-2003	Krieg et al.	
	A83	2003-0148316 A1	08-07-2003	Lipford et al.	
	A84	2003-0148976 A1	08-07-2003	Krieg et al.	
	A85	2003-0181406 A1	09-25-2003	Schetter et al.	
	A86	2003-0212026 A1	11-13-2003	Krieg et al.	
	A87	2003-0224010 A1	12-04-2003	Davis et al.	
	A88	2003-0232074 A1	12-18-2003	Lipford et al.	
	A89	2003-0232856 A1	12-18-2003	Macfarlane	
	A90	2004-0009949 A1	01-15-2004	Krieg	
	A91	2004-0030118 A1	02-12-2004	Wagner et al.	
	A92	2004-0047869 A1	03-11-2004	Garcon et al.	
	A93	2004-0053880 A1	03-18-2004	Krieg	
	A94	2004-0067902 A1	04-08-2004	Bratzler et al.	
	A95	2004-0067905 A9	04-08-2004	Krieg	
	A96	2004-0087534 A1	05-06-2004	Krieg et al.	
	A97	2004-0087538 A1	05-06-2004	Krieg et al.	
	A98	2004-0092472 A1	05-13-2004	Krieg	
	A99	2004-0131628 A1	07-08-2004	Bratzler et al.	
	A100	2004-0132685 A1	07-08-2004	Krieg et al.	
	A101	2004-0142469 A1	07-22-2004	Krieg et al.	
	A102	2004-0143112 A1	07-22-2004	Krieg et al.	
	A103	2004-0147468 A1	07-29-2004	Krieg et al.	
	A104	2004-0152649 A1	08-05-2004	Krieg	
	A105	2004-0152656 A1	08-05-2004	Krieg et al.	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: June 8, 2009 <i>(use as many sheets as necessary)</i>		Application Number	09/506,011
		Filing Date	02/17/2000
		First Named Inventor	John Cooper Cox
		Art Unit	1648
		Examiner Name	Emily M. Le
Sheet 4 of 25	Attorney Docket Number	017227-0155	

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A106	2004-0152657 A1	08-05-2004	Krieg et al.	
	A107	2004-0162258 A1	08-19-2004	Krieg et al.	
	A108	2004-0162262 A1	08-19-2004	Krieg et al.	
	A109	2004-0167089 A1	08-26-2004	Krieg et al.	
	A110	2004-0171150 A1	09-02-2004	Krieg et al.	
	A111	2004-0171571 A1	09-02-2004	Krieg et al.	
	A112	2004-0181045 A1	09-16-2004	Krieg et al.	
	A113	2004-0198680 A1	10-07-2004	Krieg	
	A114	2004-0198688 A1	10-07-2004	Krieg et al.	
	A115	2004-0229835 A1	11-18-2004	Krieg et al.	
	A116	2004-0234512 A1	11-25-2004	Wagner et al.	
	A117	2004-0235770 A1	11-25-2004	Davis et al.	
	A118	2004-0235774 A1	11-25-2004	Bratzler et al.	
	A119	2004-0235777 A1	11-25-2004	Wagner et al.	
	A120	2004-0235778 A1	11-25-2004	Wagner et al.	
	A121	2005-0004061 A1	01-06-2005	Krieg et al.	
	A122	2005-0004062 A1	01-06-2005	Krieg et al.	
	A123	2005-0009774 A1	01-13-2005	Krieg et al.	
	A124	2005-0032734 A1	02-10-2005	Davis et al.	
	A125	2005-0032736 A1	02-10-2005	Krieg et al.	
	A126	2005-0037403 A1	02-17-2005	Krieg et al.	
	A127	2005-0043529 A1	02-24-2005	Davis et al.	
	A128	2005-0049215 A1	03-03-2005	Krieg et al.	
	A129	2005-0049216 A1	03-03-2005	Krieg et al.	
	A130	2005-0054601 A1	03-10-2005	Wagner et al.	
	A131	2005-0054602 A1	03-10-2005	Krieg et al.	
	A132	2005-0059619 A1	03-17-2005	Krieg et al.	
	A133	2005-0059625 A1	03-17-2005	Krieg et al.	
	A134	2005-0070491 A1	03-31-2005	Krieg et al.	
	A135	2005-0075302 A1	04-07-2005	Hutcherson et al.	
	A136	2005-0100983 A1	05-12-2005	Bauer et al.	
	A137	2005-0101557 A1	05-12-2005	Krieg et al.	
	A138	2005-0123523 A1	06-09-2005	Krieg et al.	
	A139	2005-0148537 A1	07-07-2005	Krieg et al.	
	A140	2005-0169888 A1	08-04-2005	Hartman et al.	
	A141	2005-0171047 A1	08-04-2005	Krieg et al.	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: June 8, 2009 <i>(use as many sheets as necessary)</i>				Application Number	09/506,011
				Filing Date	02/17/2000
				First Named Inventor	John Cooper Cox
				Art Unit	1648
				Examiner Name	Emily M. Le
Sheet	5	of	25	Attorney Docket Number	017227-0155

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A142	2005-0181035 A1	08-18-2005	Dow et al	
	A143	2005-0181422 A1	08-18-2005	Bauer et al.	
	A144	2005-0182017 A1	08-18-2005	Krieg	
	A145	2005-0197314 A1	09-08-2005	Krieg et al.	
	A146	2005-0215500 A1	09-29-2005	Krieg et al.	
	A147	2005-0222072 A1	10-16-2005	Wang et al.	
	A148	2005-0233995 A1	10-20-2005	Krieg et al.	
	A149	2005-0233999 A1	10-20-2005	Krieg et al.	
	A150	2005-0239732 A1	10-27-2005	Krieg et al.	
	A151	2005-0239733 A1	10-27-2005	Lurk et al.	
	A152	2005-0239734 A1	10-27-2005	Uhlmann et al.	
	A153	2005-0239736 A1	10-27-2005	Krieg et al.	
	A154	2005-0245477 A1	11-03-2005	Krieg et al.	
	A155	2005-0244379 A1	11-03-2005	Krieg et al.	
	A156	2005-0244380 A1	11-03-2005	Krieg et al.	
	A157	2005-0250726 A1	11-10-2005	Krieg et al.	
	A158	2005-0256073 A1	11-17-2005	Lipford et al.	
	A159	2005-0267057 A1	12-01-2005	Krieg	
	A160	2005-0267064 A1	12-01-2005	Krieg et al.	
	A161	2005-0277604 A1	12-15-2005	Krieg et al.	
	A162	2005-0277609 A1	12-15-2005	Krieg et al.	
	A163	2006-0003955 A1	01-05-2006	Krieg et al.	
	A164	2006-0019916 A1	01-26-2006	Krieg et al.	
	A165	2006-0089326 A1	04-27-2006	Krieg et al.	
	A166	2006-0094683 A1	05-04-2006	Krieg et al.	
	A167	2006-0140875 A1	06-29-2006	Krieg et al.	
	A168	2006-0154890 A1	07-13-2006	Bratzler et al.	
	A169	2006-0211639 A1	09-21-2006	Bratzler et al.	
	A170	2006-0211644 A1	09-21-2006	Krieg et al.	
	A171	2006-0241076 A1	10-26-2006	Uhlmann et al.	
	A172	2006-0286070A1	12-21-2006	Hartmann et al.	
	A173	2007-0065467A1	03-22-2007	Krieg et al.	
	A174	2007-0066554A1	03-22-2007	Krieg et al.	
	A175	2007-0078104A1	04-05-2007	Krieg et al.	
	A176	2007-0037767A1	02-15-2007	Bratzler et al.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: June 8, 2009 (use as many sheets as necessary)			Complete if Known	
			Application Number	09/506,011
Sheet 6 of 25			Filing Date	02/17/2000
			First Named Inventor	John Cooper Cox
			Art Unit	1648
			Examiner Name	Emily M. Le
			Attorney Docket Number	017227-0155

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A177	2007-0224210A1	09-27-2007	Krieg et al.	
	A178	2007-0184465A1	08-09-2007	Wagner et al.	
	A179	2008-0031936A1	02-07-2008	Krieg et al.	
	A180	4,469,863	09-04-1984	TS'O et al.	
	A181	5,023,243	06-11-1991	Tullis	
	A182	5,177,198	01-05-1993	Spielvogel et al.	
	A183	5,859,231	01-12-1999	Shaw et al.	
	A184	6,160,109	12-12-2000	Just et al.	
	A185	2003-0104523	06-05-2003	Bauer et al.	
	A186	6,251,603	06-26-2001	Jager et al.	
	A187	6,639,814	10-2003	Gan et al.	
	A188	5,443,534	08-1995	Vinciarelli et al.	
	A189	2003/0059937	03-2003	Ruben et al.	
	A190	2003/0175884	09-2003	Umana et al.	
	A191	5,612,030	03-18-1997	Chatterjee et al.	
	A192	5,716,848	02-10-1998	Dalsgard et al.	
	A193	6,190,870	02-20-2001	Schmitz et al.	
	A194	6,231,859	05-15-2001	Kensil	
	A195	6,355,244	03/12/2002	Foon et al.	

UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Application Document	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Serial Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	A196	EP 0 109 942 B1	03-06-1991	Morein, Bror		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: June 8, 2009 <i>(use as many sheets as necessary)</i>			Application Number	09/506,011	
			Filing Date	02/17/2000	
			First Named Inventor	John Cooper Cox	
			Art Unit	1648	
			Examiner Name	Emily M. Le	
Sheet	7	of	25	Attorney Docket Number	017227-0155

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	A197	EP 0 180 564 B1	05-07-1986	Morein, Bror		
	A198	WO 98/22135 A1	05-28-1998	Astra Aktiebolag		
	A199	WO 98/36772 A1	08-27-1998	CSL Limited		
	A200	EP 0 231 039 B1	01-08-1992	Nederlanden Staat		
	A201	WO 00/09159 A1	02-24-2000	Aquila Biopharaceuticals		
	A202	WO 00/15256 A2	03-23-2000	Pasteur Merieux Serums		
	A203	WO 00/62800 A2	10-26-2000	Smithkline Beecham Biol.		
	A204	WO 00/67787 A2	11-16-2000	Immune Response Corp.		
	A205	WO 01/35991 A2	05-25-2001	Dynavax Tech. Corp.		
	A206	WO 02/28428 A2	04-11-2002	Aventis Pasteur		ABS.
	A207	WO 02/32450 A2	04-25-2002	Smithkline Beecham Biol.		
	A208	WO 05/004910 A2	01-20-2005	Intercell AG		
	A209	WO 90/03184 A1	04-05-1990	Morein, Bror et al.		
	A210	WO 00/41720 A1	07-20-2000	CSL Limited		
	A211	WO 01/37879 A1	05-31-2001	Nanocarrier Co. Ltd.		ABS.
	A212	WO 04/039950 A2	05-13-2004	Chiron Corporation		
	A213	WO 01/15727 A2	03-08-2001	Aquila Biopharmaceuticals Inc.		
	A214	WO 01/51083 A2	07-19-2001	Aquila Biopharmaceuticals Inc.		
	A215	WO 99/61056 A2	12-02-1999	Loeb Health Research Inst.		
	A216	WO 95/09179 A1	04-06-1995	Seed Capital Investment B.V.		
	A217	WO 2007/026190 A2	03-08-2007	CSL Limited		
	A218	WO 94/25602 A1	11-10-1994	Common Services Agency		
	A219	WO 00/07621	02-17-2000	Smithkline Beecham Biolog.		
	A220	WO 98/15287	04-16-1998	Smithkline Beecham Biolog.		
	A221	WO 99/11241	03-11-1999	Smithkline Beecham Biolog.		
	A222	WO 99/12565	03-18-1999	Smithkline Beecham Biolog.		
	A223	WO 96/11711	04-25-1996	Iscotec AB		
	A224	EP 0468520 A2	01-29-1992	Mitsui Toatsu Chemicals, Inc.		
	A225	WO 96/02555 A1	02-01-1996	University of Iowa Research Foundation		
	A226	WO 99/56755 A1	11-11-1999	University of Iowa Research Foundation		
	A227	WO 00/06588 A1	02-10-2000	University of Iowa Research Foundation		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: June 8, 2009 (use as many sheets as necessary)		Complete if Known	
		Application Number Filing Date First Named Inventor Art Unit Examiner Name Attorney Docket Number	09/506,011 02/17/2000 John Cooper Cox 1648 Emily M. Le 017227-0155
Sheet	8	of	25

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	A228	WO 00/15256 A2	03-23-2000	Pasteur Meraux Serums Et Vaccines [FR]		
	A229	WO 00/54803 A2	09-21-2000	Panacea Pharmaceuticals, LLC.		
	A230	WO 00/75304 A1	12-14-2000	Aventis Pasteur [FR]		
	A231	WO 01/45750 A1	06-28-2001	Regents of the University of California		
	A232	WO 01/62909 A1	08-30-2001	Aventis Pasteur [FR]		
	A233	WO 2004/007743 A2	01-22-2004	Coley Pharmaceutical GmbH		
	A234	WO 2004/026888 A2	04-01-2004	Coley Pharmaceutical GmbH		
	A235	WO 2004/094671 A2	11-04-2004	Coley Pharmaceutical GmbH		
	A236	EP 0 092 574 B1	04-29-1992	Molecular Biosystems, Inc.		
	A237	WO 95/01363 A1	01-12-1995	Hoechst Aktiengesellschaft		
	A238	WO 96/33739 A1	10-31-1996	SmithKline Beecham Biologicals S.a.		
	A239	WO 98/18810 A1	05-07-1998	The University of Iowa Research Foundation		
	A240	WO 00/14217 A2	03-16-2000	Cpg Immunopharmaceuticals GmbH		
	A241	WO 01/22990 A2	04-05-2001	Coley Pharmaceutical Group, Inc., et al.		
	A242	WO 01/07917 A1	02-01-2001	Ludwig Inst. Cancer Res.		
	A243	WO 03/040299 A2	05-15-2003	Commissariat A L'Energie Atomique; Sedac Therapeutics		
	A244	WO 2005/026370 A2	03-24-2005	Aventis Pasteur Limited		
	A245	WO 2005/033278 A2	04-14-2005	Ludwig Inst. Cancer Res.		
	A246	WO 99/53938	10-28-1999	Ludwig Inst. Cancer Res.		
	A247	WO 98/40100	09-17-1998	Ottawa Civic Loeb Research Institute		
	A248	WO 99/61056	12-02-1999	Loeb Health Research Institute at the Ottawa Hospital		
	A249	WO 01/15727	03-08-2001	Antigenics, Inc.		
	A250	WO 01/22972	04-05-2001	University of Iowa Research Foundation		
	A251	WO 01/51083	07-19-2001	Antigenics, Inc.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: June 8, 2009 (use as many sheets as necessary)		Application Number	09/506,011
		Filing Date	02/17/2000
		First Named Inventor	John Cooper Cox
		Art Unit	1648
		Examiner Name	Emily M. Le
Sheet	9	of	25
		Attorney Docket Number	017227-0155

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A252	MOREIN et al., "Functional aspects of isocoms," <i>Immunology & Cell Biology</i> , Vol. 76, 1998, pages 295-299.	
	A253	COULTER et al., "Studies on experimental adjuvanted influenza vaccines: comparison of immune stimulating complexes (Iscoms™) and oil-in-water vaccines," <i>Vaccine</i> , 1997, pp. 1243-1253, Vol. 16, No. 11/12, Elsevier Science Ltd., Great Britain	
	A254	DASS et al., Immunostimulatory activity of cationic-lipid-nucleic-acid complexes against cancer. <i>J Cancer Res Clin Oncol</i> . 2002 Apr; 128(4): 177-81.	
	A255	EVANS et al., The use of ISCOMATRIX adjuvant for delivery of CpG 7909. July 2004 Meeting. Poster and Abstract.	
	A256	GOUTTEFANGEAS et al., Problem solving for tumor immunotherapy. <i>Nat Biotechnol</i> . 2000 May; 18(5):491-2.	
	A257	GREGORIADIS et al. (Eds.), <i>Vaccine Design, The Role of Cytokine Networks</i> , 1996, TABLE OF CONTENTS ONLY, Plenum Press	
	A258	GROSSMANN et al., Avoiding tolerance against prostatic antigens with subdominant peptide epitopes. <i>J Immunother</i> . 2001 May-Jun; 24(3):237-41.	
	A259	HARTMANN et al., "CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells," <i>Proc. Natl. Acad. Sci. USA</i> , August 1999, pp. 9305-9310, Vol. 96	
	A260	HARTMANN et al., <i>J. Immunol.</i> , Vol. 164, 2000, pages 1617-1624.	
	A261	LIU et al., CpG ODN is an effective adjuvant in immunization with tumor antigen. <i>J Invest Med</i> . 1997 Sept 7; 45(7):333A.	
	A262	O'HAGAN et al., Recent developments in vaccine delivery systems. <i>Curr Drug Targets Infect Disord</i> . 2001 Nov; 1(3):273-86.	
	A263	SINGH et al., Recent advances in vaccine adjuvants. <i>Pharm Res</i> . 2002 Jun; 19(6):715-28.	
	A264	SINGH et al., Recent advances in veterinary vaccine adjuvants. <i>Int J Parasitol</i> . 2003 May; 33(5-6):469-78.	
	A265	BOMFORD et al., 1992, "Adjuvanticity and ISCOM Formation by Structurally Diverse Saponins," <i>Vaccine</i> 10(9):572-7.	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	09/506,011
		Filing Date	02/17/2000
		First Named Inventor	John Cooper Cox
		Art Unit	1648
		Examiner Name	Emily M. Le
Date Submitted: June 8, 2009		Attorney Docket Number	017227-0155
(use as many sheets as necessary)			
Sheet	10	of	25

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A266	BOMFORD, 1982, "Studies on the Cellular Site of Action of the Adjuvant Activity of Saponin for Sheep Erythrocytes," Int. Arch. Allergy Appl. Immunol. 67(2):127-31.	
	A267	CAMPBELL et al., 1992, "Saponin," Res. Immunol. 143(5):526-30; discussion 577-8.	
	A268	COUGHLIN et al., 1995, Adjuvant Activity of QS-21 for Experimental E. Coli 018 Polysaccharide Vaccines," Vaccine 13(1); 17-21	
	A269	DALSGAARD, 1974, "Saponin Adjuvants. 3. Isolation of a Substance from Quillaja Saponaria Molina with Adjuvant Activity in Food-and-Mouth Disease Vaccines," Arch. Gesamte. Virusforsch.. 44(3):243-54	
	A270	ESTRADA et al., 1998, "Adjuvant Action of Chenopodium Quinoa Saponins on the Induction of Antibody Responses to Intragastric and Intranasal Administered Antigens in Mice", Comp. Immunol. Microbiol. Infect. Dis. 21(3):225-36	
	A271	HANCOCK et al, 1995, "Formulation of the Purified Fusion Protein of Respiratory Syncytial Virus with the Saponin QS-21 Induces Protective Immune Responses in Balb/c Mice that are similar to those generated by Experimental Infection," Vaccine 13(4):391-400.	
	A272	HIGUCHI et al., 1987, "Structure of Desacylsaponins Obtained from the Bark of Quillaja Saponaria," Phytochemistry 26:229-35	
	A273	KENSIL et al., 1991, "Separation and Characterization of Saponins with Adjuvant Activity from Quillaja Saponaria Molina Cortex," J. Immunol. 146(2):431-7	
	A274	SOLTYSIK et al., 1993, "Adjuvant Activity of QS-21 Isomers," Ann. N.Y. Acad. Sci. 690:392-5	
	A275	KENSIL et al., 1995, "Structural and Immunological Characterization of the Vaccine adjuvant QS-21," Vaccine Design: The Subunit and Adjuvant Approach, Powell and Nuwman eds., Plenum Press, New York	
	A276	KERSTEN et al., "Incorporation of the Major Outer Membrane Protein of Neisseria Gonorrhoeae in Saponin-Lipid Complese (Isocomes); Chemuical Analysis, Some Structural Features, and Comparison of Their Immunogenicity with Three Other Antigen Delivery Systems," Infect. Immun. 56(2):432-8.	
	A277	LACAILLE-DUBOIS et al., 1996, "A Review of the Biological and Pharmacological Activities of Saponins," Phytomedicine Vol. 2, 363-386.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: June 8, 2009 (use as many sheets as necessary)		Complete if Known	
		Application Number Filing Date First Named Inventor Art Unit Examiner Name	09/506,011 02/17/2000 John Cooper Cox 1648 Emily M. Le
Sheet 11 of 25	Attorney Docket Number 017227-0155		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A278	LIVINGSTON et al., 1994, "Phase I Trial of Immunological Adjuvant QS-21 with a GM2 Ganglioside-Keyhole Limpet Haemocyanin Conjugate Vaccine in Patients with Malignant Melanoma," Vaccine 12(14):1275-80.	
	A279	MA et al., "Impact of the Saponin Adjuvant QS-21 and Aluminum Hydroxide on the Immunogenicity of Recombinant OspA and OspB of Borrelia burgdorferi," Vaccine 12(10):925	
	A280	NEWMAN et al., 1992, "Saponin Adjuvant Induction of Ovalbumin-Specific CD8+ Cytotoxic T Lymphocyte Responses," J. Immunol. 148(8):2357-62	
	A281	SOLTYSIK et al., 1995, "Structure/function Studies of QS-21 Adjuvant: Assessment of Triterpene Aldehyde and Glucuronic Acid Roles in Adjuvant Function," Vaccine 13(15):1403-10	
	A282	WHITE et al., 1991, "A Purified Saponin Acts as an Adjuvant for a T-independent Antigen," Immunobiology of Proteins and Peptides, Vol. VI (Atassi ed.), Plenum Press, New York, 207-210.	
	A283	WU et al., 1992, "Saponin Adjuvant Enhancement of Antigen-Specific Immune Responses to an Experimental HIV-I Vaccine," J. Immunol. 148(5):1519-25	
	A284	WU et al., 1994, "Accessory Cell Requirements for Saponin Adjuvant-Induced Class I MHC Antigen-Restricted Cytotoxic T-Lymphocytes," Cell. Immunol. 154(a):393-406	
	A285	HITOMI et al., "High Efficiency Prokaryotic Expression and Purification of a Portion of the Hepatitis C Core Protein and Analysis of the Immune Response to Recombinant Protein in BALB/c Mice," Viral Immunology, Vol. 8, No. 2, 1995, pages 109-119.	
	A286	KHEMKA et al. "The Capacity of a Combined Liposomal Hepatitis B and C Vaccine to Stimulate Humoral and Cellular Responses in Mice," Viral Immunology, Vol. 11, No. 2, 1998, pages 73-78.	
	A287	LAMONACA et al., "Conserved Hepatitis C Virus Sequences are Highly Immunogenic for CD4 ⁺ T Cells: Implications for Vaccine Development," Hepatology, Vol. 30, No. 4, October 1999, pages 1088-1098.	
	A288	POLAKOS et al., "Characterization of Hepatitis C Virus Core-Specific Immune Responses Primed in Rhesus Macaques by a Nonclassical ISCOM Vaccine," Journal of Immunology, Vol. 166, No. 5, March 1, 2001, pages 3589-3598.	
	A289	LEE et al. "Identification of a Domain Containing B-Cell Epitopes in Hepatitis C Virus E2 Glycoprotein by Using Mouse Monoclonal Antibodies," Journal of Virology, Vol. 73, No. 1, January 1999, pages 11-18.	
	A290	SJOLANDER et al., <i>Advanced Drug Delivery Reviews</i> , Vol. 34, Issues 2-3, 1 December 1998, pages 321-338.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: June 8, 2009 (use as many sheets as necessary)				Complete if Known	
				Application Number	09/506,011
				Filing Date	02/17/2000
				First Named Inventor	John Cooper Cox
				Art Unit	1648
				Examiner Name	Emily M. Le
Sheet	12	of	25	Attorney Docket Number	017227-0155

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A291	CERNY et al., <i>J. Clin. Invest.</i> , Vol. 95, No. 2, Feb. 1995, pages 521-530.	
	A292	CRUSE et al., <i>Illustrated Dictionary of Immunology</i> , 2 nd edition, published on 2003 by CRC, pages 577-578.	
	A293	SELBY et al., "Expression, identification and subcellular localization of the proteins encoded by the hepatitis C Viral genome", <i>J. of General Virology</i> , Vol. 74, 1993, pages, 1103-1113.	
	A294	CHRISTIE et al., <i>Hepatology</i> , Vol. 30, No. 4, 1999, pages 1037-1044.	
	A295	FARCI et al., <i>Science</i> , Vol 288, 2000, pages 399-344.	
	A296	COOPER et al., <i>Immunity</i> , Vol. 10, 1999, pages 439-449.	
	A297	AGRAWAL et al., Chapter 19: Pharmacokinetics and bioavailability of antisense oligonucleotides following oral and colorectal administrations in experimental animals. 1998: 525-43.	
	A298	AGRAWAL et al., Antisense oligonucleotides: towards clinical trials. Trends in Biotechnology, 1996; 14: 376-87.	
	A299	ASKEW et al., CpG DNA induces maturation of dendritic cells with distinct effects on nascent and recycling MHC-II antigen-processing mechanisms. J Immunol. 2000 Dec 15;165(12):6889-95.	
	A300	BARAL et al., Immunostimulatory CpG oligonucleotides enhance the immune response of anti-idiotypic vaccine that mimics carcinoembryonic antigen. Cancer Immunol Immunother. 2003 May; 52(5):317-27.	
	A301	CARPENTIER et al., Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs. Clin Cancer Res. 2000 Jun; 6(6):2469-73.	
	A302	CHOI et al., The level of protection against rotavirus shedding in mice following immunization with a chimeric VP6 protein is dependent on the route and the coadministered adjuvant. Vaccine. 2002 Mar 15;20(13-14):1733-40.	
	A303	CHU et al., CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med. 1997 Nov 17; 186(10):1623-31.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: June 8, 2009 <i>(use as many sheets as necessary)</i>		Application Number	09/506,011
		Filing Date	02/17/2000
		First Named Inventor	John Cooper Cox
		Art Unit	1648
		Examiner Name	Emily M. Le
Sheet	13	of	25
		Attorney Docket Number	017227-0155

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A304	COOPER et al., Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluorix influenza vaccine. Vaccine. 2004 Aug 13; 22(23-24):3136-43.	
	A305	CROOKE et al., Phosphorothioate Oligonucleotides. Therapeut Apps. 1995; ch5:63-84.	
	A306	DAFTARIAN et al., Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors. Cancer Res. 2004 Aug 1;64(15):5407-14.	
	A307	DAVILA et al., Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Cancer Res. 2003 Jun. 15; 63(12):3281-8.	
	A308	DAVIS et al., CpG ODN is safe and highly effective in humans as adjuvant to HBV vaccine: Preliminary results of Phase I trial with CpG ODN 7909. Third Annual Conference on Vaccine Res. 2000. Abstract s25, number 47.	
	A309	GALLICHAN et al., Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J Immunol. 2001 Mar 1; 166(5):3451-7.	
	A310	GARBI et al., CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction. J Immunol. 2004 May 15; 172(10):5861-9.	
	A311	HOLMGREN et al., Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Expert Rev Vaccines. 2003 Apr; 2(2):205-17.	
	A312	JAKOB et al., Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J Immunol. 1998 Sep 15; 161(6):3042-9.	
	A313	JAKOB et al., Bacterial DNA and CpG-containing oligodeoxynucleotides activate cutaneous dendritic cells and induce IL-12 production: implications for the augmentation of Th1 responses. Int Arch Allergy Immunol. 1999 Feb-Apr; 118(2-4):457-61.	
	A314	KLINMAN et al., Immunotherapeutic applications of CpG-containing oligodeoxynucleotides. Drug News Perspect. 2000 Jun; 13(5):289-96.	
	A315	KOVARIK et al., CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming. J Immunol. 1999 Feb 1; 162(3):1611-7.	
	A316	KRIEG et al., Applications of immune stimulatory CpG DNA for antigen-specific and antigen-nonspecific cancer immunotherapy. Eur J Canc. 1999 Oct; 35/Supp14:S10. Abstract #14.	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	09/506,011
		Filing Date	02/17/2000
		First Named Inventor	John Cooper Cox
		Art Unit	1648
		Examiner Name	Emily M. Le
Date Submitted: June 8, 2009		Attorney Docket Number	017227-0155
(use as many sheets as necessary)			
Sheet	14	of	25

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A317	KRIEG et al., Causing a commotion in the blood: immunotherapy progresses from bacteria to bacterial DNA. Immunol Today. 2000 Oct; 21(10):521-6.	
	A318	KRIEG et al., Enhancing vaccines with immune stimulatory CpG DNA. Curr Opin Mol Ther. 2001 Feb; 3(1): 15-24.	
	A319	KRIEG et al., Chapter 7: CpG oligonucleotides as immune adjuvants. Ernst Schering Research Found Workshop 2001; 30: 105-18.	
	A320	KRIEG, Immune effects and mechanisms of action of CpG motifs. Vaccine. 2000 Nov 8; 19(6):618-22.	
	A321	KRIEG et al., Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J Immunother. 2004 Nov-Dec; 27(6):460-71.	
	A322	KURAMOTO et al., Induction of T-cell-mediated immunity against MethA fibrosarcoma by intratumoral injections of a bacillus Calmette-Guerin nucleic acid fraction. Cancer Immunol Immunother. 1992; 34(5):283-8.	
	A323	LEE et al., Immuno-stimulatory effects of bacterial-derived plasmids depend on the nature of the antigen in intramuscular DNA inoculations. Immunology. 1998 Jul; 94(3):285-9.	
	A324	LIPFORD et al., CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur J Immunol. 1997 Sep; 27(9):2340-4.	
	A325	LIPFORD et al., Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines. Eur J Immunol. 1997 Dec; 27(12):3420-6.	
	A326	LIU et al., CpG ODN is an effective adjuvant in immunization with tumor antigen. J Invest Med. 1997 Sept 7; 45(7):333A.	
	A327	LONSDORF et al., Intratumor CpG-oligodeoxynucleotide injection induces protective antitumor T cell immunity. J Immunol. 2003 Oct 15; 171(8):3941-6.	
	A328	MAGNUSSON et al., Importance of CpG dinucleotides in activation of natural IFN-alpha-producing cells by a lupus-related oligodeoxynucleotide. Scand J Immunol. 2001 Dec; 54(6):543-50.	
	A329	McCLUSKIE et al., CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J Immunol. 1998 Nov 1; 161 (9):4463-6.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: June 8, 2009 <i>(use as many sheets as necessary)</i>		Application Number	09/506,011
		Filing Date	02/17/2000
		First Named Inventor	John Cooper Cox
		Art Unit	1648
		Examiner Name	Emily M. Le
Sheet	15	of	25
		Attorney Docket Number	017227-0155

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A330	McCLUSKIE et al., CpG DNA as mucosal adjuvant. Vaccine, 18: 231-237, 2000.	
	A331	McCLUSKIE et al., Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants. Vaccine. 2000 Oct 15; 19(4-5):413-22.	
	A332	McCLUSKIE et al., CpG DNA is an effective oral adjuvant to protein antigens in mice. Vaccine. 2000 Nov 22; 19(7-8):950-7.	
	A333	McCLUSKIE et al., The potential of oligodeoxynucleotides as mucosal and parenteral adjuvants. Vaccine. 2001 Mar 21; 19(17-19):2657-60.	
	A334	McCLUSKIE et al., The use of CpG DNA as a mucosal vaccine adjuvant. Curr Opin Investig Drugs. 2001 Jan; 2(1):35-9.	
	A335	McCLUSKIE et al., The role of CpG in DNA vaccines. Springer Semin Immunopathol. 2000; 22(1-2):125-32.	
	A336	MICONNET et al., CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide. J Immunol. 2002 Feb 1; 168(3):1212-8.	
	A337	O'HAGAN et al., Recent developments in adjuvants for vaccines against infectious diseases. Biomol Eng. 2001 Oct 15; 18(3):69-85.	
	A338	PAYETTE et al., History of vaccines and positioning of current trends. Curr Drug Targets Infect Disord. 2001 Nov; 1(3):241-7.	
	A339	REVAZ et al., The importance of mucosal immunity in defense against epithelial cancers. Curr Opin Immunol. 2005 Apr; 17(2): 175-9.	
	A340	ROMAN et al., Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med. 1997 Aug; 3(8):849-54.	
	A341	SONEHARA et al., Hexamer palindromic oligonucleotides with 5'-CG-3' motif(s) induce production of interferon. J Interferon Cytokine Res. 1996 Oct; 16(10):799-803.	
	A342	THREADGILL et al., Mitogenic synthetic polynucleotides suppress the antibody response to a bacterial polysaccharide. Vaccine. 1998 Jan; 16(1):76-82.	
	A343	TORTORA et al., Oral antisense that targets protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis, and growth factor production. Clin Cancer Res. 2000 Jun; 6(6):2506-12.	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: June 8, 2009 (use as many sheets as necessary)		Application Number	09/506,011
		Filing Date	02/17/2000
		First Named Inventor	John Cooper Cox
		Art Unit	1648
		Examiner Name	Emily M. Le
Sheet	16	of	25
		Attorney Docket Number	017227-0155

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A344	VICARI et al., Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J Exp Med. 2002 Aug 19; 196(4):541-9.	
	A345	WAGNER et al., CpG motifs are efficient adjuvants for genetic vaccines to induce antigen-specific protective anti-tumor T cell responses. 2000; 203:429. Abstract R46.	
	A346	WANG et al., Synergy between CpG- or non-CpG DNA and specific antigen for B cell activation. Int Immunol. 2003 Feb; 15(2):223-31.	
	A347	WEERATNA et al., CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice. FEMS Immunol Med Microbiol. 2001 Dec; 32(1):65-71.	
	A348	WEINER et al., Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci USA. 1997 Sep 30; 94(20): 10833-7.	
	A349	WERNETTE et al., CpG oligodeoxynucleotides stimulate canine and feline immune cell proliferation. Vet Immunol Immunopathol. 2002 Jan 15; 84(3-4):223-36.	
	A350	YAMAMOTO et al., Lipofection of synthetic oligodeoxyribonucleotide having a palindromic sequence of AACGTT to murine splenocytes enhances interferon production and natural killer activity. Microbiol Immunol. 1994; 38(10):831-6.	
	A351	WEIGEL et al., "CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma," Clin. Cancer Res., August 2003, Vol. 9, No. 8, pages 3105-3114.	
	A352	AGRAWAL (Ed.), Methods in Molecular Biology., "Protocols for Oligonucleotides and Analogs, Synthesis and Properties," TABLE OF CONTENTS ONLY, Humana Press, Totowa, New Jersey	
	A353	ABUCHOWSKI et al., "Soluble Polymer-Enzyme Adducts," Enzymes as Drugs, Chapter 13, 1981, pp. 367-383, John Wiley & Sons	
	A354	ACKLEY et al., "Immunologic Abnormalities in Pathogen-Free Cats Experimentally Infected with Feline Immunodeficiency Virus," Journal of Virology, Nov. 1990, pp. 5652-5655, Vol. 64, No. 11, American Society for Microbiology	
	A355	ADJEI et al., "Pulmonary Delivery of Peptide Drugs: Effect of Particle Size on Bioavailability of Leuprolide Acetate in Healthy Male Volunteers," Pharmaceutical Research, June 1990, pp. 565-569, Vol. 7, No. 6, Plenum Press	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: June 8, 2009 (use as many sheets as necessary)		Complete if Known	
		Application Number Filing Date First Named Inventor Art Unit Examiner Name Attorney Docket Number	09/506,011 02/17/2000 John Cooper Cox 1648 Emily M. Le 017227-0155
Sheet	17	of	25

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A356	SJÖDIN et al., "Radioreceptor assay for formulations of salmon calcitonin," <u>International Journal of Pharmaceutics</u> , 1990, pp. 135-142, Vol. 63, Elsevier Science Publishers B.V.	
	A357	BALLAS et al., "Induction of NK Activity in Murine and Human Cells by CpG Motifs in Oligodeoxynucleotides and Bacterial DNA," <u>The Journal of Immunology</u> , 1996, pp. 1840-1845	
	A358	BERMAN et al., "Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160," <u>Nature</u> , 14 June 1990, pp. 622-625, Vol. 345	
	A359	BRAQUET et al., "Effect of Endothelin-1 on Blood Pressure and Bronchopulmonary System of the Guinea Pig," <u>Journal of Cardiovascular Pharmacology</u> , 1989, pp. S143-S146, Vol. 13, Suppl. 5, Raven Press	
	A360	BÜLOW et al., "Erhohte Pathogenität des Erregers der aviären infektiösen Anämie bei Hühnerkuken (CAA) bei simultaner Infektion mit Virus der Marekschen Krankheit (MDV), Bursitisvirus (IBDV) oder Reticuloendotheliosevirus (REV)," <u>J. Vet. Med. B</u> , 1986, pp. 93-116, Vol. 33, Paul Parey Scientific Publishers	
	A361	THOMAS (Ed.), <u>Medical Microbiology</u> , 5 th Edition, 1983, TABLE OF CONTENTS ONLY, Bailliere Tindall, Great Britain	
	A362	CARLSON et al., "Vaccine Protection of Rhesus Macaques Against Simian Immunodeficiency Virus Infection," <u>AIDS Research and Human Retroviruses</u> , 1990, pp. 1239-1246, Vol. 6, No. 11, Mary Ann Liebert, Inc.	
	A363	COHEN et al., "CD4 ⁺ T-Cells from Mice Immunized to Syngeneic Sarcomas Recognize Distinct, Non-Shared Tumor Antigens," <u>Cancer Research</u> , February 15, 1994, pp. 1055-1058, Vol. 54	
	A364	COULTER et al., "Studies on experimental adjuvanted influenza vaccines: comparison of immune stimulating complexes (Iscoms TM) and oil-in-water vaccines," <u>Vaccine</u> , 1997, pp. 1243-1253, Vol. 16, No. 11/12, Elsevier Science Ltd., Great Britain	
	A365	CROOKE et al., "Progress in Antisense Oligonucleotide Therapeutics," <u>Annu. Rev. Pharmacol. Toxicol.</u> , 1996, pp. 107-129, Annual Reviews Inc.	
	A366	DEBS et al., "Lung-Specific Delivery of Cytokines Induces Sustained Pulmonary and Systemic Immunomodulation in Rats," <u>The Journal of Immunology</u> , May 15, 1998, pp. 3482-3488, Vol. 140, No. 10, The American Association of Immunologists, USA	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: June 8, 2009 <i>(use as many sheets as necessary)</i>		Application Number	09/506,011
		Filing Date	02/17/2000
		First Named Inventor	John Cooper Cox
		Art Unit	1648
		Examiner Name	Emily M. Le
Sheet	18	of	25
		Attorney Docket Number	017227-0155

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A367	DESROSIERS et al., "Vaccine protection against simian immunodeficiency virus infection," <u>Proc. Natl. Acad. Sci. USA</u> , August 1989, pp. 6353-6357, Vol. 86	
	A368	DURAND et al., "Triple-Helix Formation by an Oligonucleotide Containing One (dA) ₁₂ and Two (dT) ₁₂ Sequences Bridged by Two Hexaethylene Glycol Chains," <u>Biochemistry</u> , 1992, pp. 9197-9204, Vol. 31, No. 38, American Chemical Society	
	A369	ECKSTEIN (ed.), <u>Oligonucleotides and Analogues, A Practical Approach</u> , 1991, TABLE OF CONTENTS ONLY, Oxford University Press, New York	
	A370	FONTANEL et al., "Sterical recognition by T ₄ polynucleotide kinase of non-nucleosidic moieties 5'-attached to oligonucleotides," <u>Nucleic Acids Research</u> , 1994, pp. 2022-2027, Vol. 22, No. 11, Oxford University Press	
	A371	FROEHLER et al., "Triple-Helix Formation by Oligodeoxynucleotides Containing the Carbocyclic Analogs of Thymidine and 5-Methyl-2'-deoxycytidine," <u>J. Am. Chem. Soc.</u> , 1992, pp. 8320-8322, Vol. 114, American Chemical Society	
	A372	GOODCHILD, "Conjugates of Oligonucleotides and Modified Oligonucleotides: A Review of Their Synthesis and Properties," <u>Bioconjugate Chemistry</u> , May/June 1990, pp. 165-187, Vol. 1, No. 3, American Chemical Society	
	A373	HUBARRD et al., "Anti-Neutrophil-Elastase Defenses of the Lower Respiratory Tract in α 1-Antitrypsin Deficiency Directly Augmented with an Aerosol of α 1-Antitrypsin," <u>Annals of Internal Medicine</u> , 1 August 1989, pp. 206-212, Vol. 111, No. 3	
	A374	RADHAKRISHNAN et al., "Modified oligonucleotides - synthesis, properties and applications," <u>Current Opinion in Molecular Therapeutics</u> , June 1999, pp. 344-358, Vol. 1, No. 3	
	A375	JIANG et al., "Pseudo-Cyclic Oligonucleotides: In Vitro and In Vivo Properties," <u>Bioorganic & Medicinal Chemistry</u> , 1999, pp. 2727-2735, Vol. 7, Elsevier Science Ltd.	
	A376	KAUFMANN (Ed.), <u>Novel Vaccination Strategies</u> , 2004, TABLE OF CONTENTS ONLY, Wiley-VCH Verlag GmbH & Co.	
	A377	KRIEG et al., "Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs," <u>Proc. Natl. Acad. Sci. USA</u> , October 1988, pp. 12631-12636, Vol. 95, The National Academy of Sciences	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: June 8, 2009 <i>(use as many sheets as necessary)</i>		Application Number	09/506,011
		Filing Date	02/17/2000
		First Named Inventor	John Cooper Cox
		Art Unit	1648
		Examiner Name	Emily M. Le
Sheet	19	of	25
		Attorney Docket Number	017227-0155

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A378	KRIEG et al., "CpG motifs in bacterial DNA trigger direct B-cell activation," <u>Nature</u> , 6 April 1995, pp. 546-549, Vol. 374	
	A379	KRIEG, "Leukocyte Stimulation by Oligodeoxynucleotides," <u>Applied Antisense Oligonucleotide Technology</u> , 1998, Chapter 24, pp. 431-448, Wiley-Liss, Inc.	
	A380	KRIEG, "Mechanisms and application of immune stimulatory CpG oligodeoxynucleotides," <u>Biochimica et Biophysica Acta</u> , 1999, pp. 107-116, Vol. 1489, Elsevier Science B.V.	
	A381	KRIEGLER, <u>Gene Transfer and Expression</u> , 1990, TABLE OF CONTENTS ONLY, Stockton Press, New York	
	A382	LANGER, "New Methods of Drug Delivery," <u>Science</u> , 28 September 1990, pp. 1527-1533, Vol. 249	
	A383	MATTEUCCI et al., "The Synthesis of Oligodeoxypyrimidines on a Polymer Support," <u>Tetrahedron Letters</u> , 1980, pp. 719-722, Vol. 21, Pergamon Press, Ltd. Great Britain	
	A384	MESSINA et al., "Stimulation of In Vitro Murine Lymphocyte Proliferation by Bacterial DNA," <u>The Journal of Immunology</u> , September 15, 1991, pp. 1759-1764, Vol. 147, No. 6, The American Association of Immunologists, USA	
	A385	MURPHEY-CORB et al., "A Formalin-Inactivated Whole SIV Vaccine Confers Protection in Macaques," <u>Science</u> , 8 December 1989, pp. 1293-1297, Vol. 246	
	A386	MURRAY (Ed.), <u>Gene Transfer and Expression Protocols</u> , 1991, TABLE OF CONTENTS ONLY, The Humana Press Inc., Clifton, New Jersey	
	A387	NEWMARK et al., "Preparation and Properties of Adducts of Streptokinase and Streptokinase-Plasmin Complex with Polyethylene Glycol and Pluronic Polyol F38," <u>Journal of Applied Biochemistry</u> , 1982, pp. 185-189, Vol. 4, Academic Press, Inc.	
	A388	NIELSEN et al., "Peptide Nucleic Acid (PNA). A DNA Mimic with a Peptide Backbone," <u>Bioconjugate Chem.</u> , 1994, pp. 3-7, Vol. 5, American Chemical Society	
	A389	OLMSTED et al., "Molecular cloning of feline immunodeficiency virus," <u>Proc. Natl. Acad. Sci. USA</u> , April 1989, pp. 2448-2452, Vol. 86	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: June 8, 2009 (use as many sheets as necessary)		Complete if Known	
		Application Number Filing Date First Named Inventor Art Unit Examiner Name Attorney Docket Number	09/506,011 02/17/2000 John Cooper Cox 1648 Emily M. Le 017227-0155
Sheet	20	of	25

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A390	OLMSTED et al., "Nucleotide sequence analysis of feline immunodeficiency virus: Genome organization and relationship to other lentiviruses," <u>Proc. Natl. Acad. Sci. USA</u> , October 1989, pp. 8088-8092, Vol. 86	
	A391	PEDERSEN et al., "Isolation of a T-Lymphotropic Virus from Domestic Cats with an Immunodeficiency-Like Syndrome," <u>Science</u> , 13 February 1987, pp. 790-793, Vol. 235	
	A392	IYER et al., "3H-1,2-Benzodithiole-3-one 1,1-Dioxide as an Improved Sulfurizing Reagent in the Solid-Phase Synthesis of Oligodeoxyribonucleoside Phosphorothioates," <u>J. Am. Chem. Soc.</u> , 1990, pp. 1253-1253, Vol. 112, American Chemical Society	
	A393	ORTIAGAO et al., "Antisense Effect of Oligodeoxynucleotides with Inverted Terminal Internucleotidic Linkages: A Minimal Modification Protecting against Nucleolytic Degradation," <u>Antisense Research & Development</u> , 1992, pp. 129-146, Vol. 2, Mary Ann Liebert, Inc.	
	A394	RANKIN et al., "An Essential Role of Th1 Responses and Interferon Gamma in Infection-Mediated Suppression of Neoplastic Growth," <u>Cancer Biology & Therapy</u> , November/December 2003, pp. 687-693, Vol. 2, No. 6, Landes Bioscience	
	A395	REN et al., "Cytokine-Dependent Anti-Viral Role of CD4-Positive T Cells in Therapeutic Vaccination Against Chronic Hepatitis B Viral Infection," <u>Journal of Medical Virology</u> , 2003, pp. 376-384, Vol. 71, Wiley-Liss, Inc.	
	A396	ROSENBERGER et al., "The Isolation and Characterization of Chicken Anemia Agent (CAA) from Broilers in the United States," <u>Avian Diseases</u> , 1989, pp. 707-713, Vol. 33	
	A397	SAMBROOK et al. (Eds.), <u>Molecular Cloning: A Laboratory Manual, Second Edition</u> , 1989, TABLE OF CONTENTS ONLY, Cold Spring Harbor Laboratory Press	
	A398	SELIGER et al., "Oligonucleotide Analogues with Terminal 3'-3'- and 5'-5'- Internucleotidic Linkages as Antisense Inhibitors of Viral Gene Expression," <u>Nucleosides & Nucleotides</u> , 1991, pp. 469-477, Vol. 10, No. 1-3, Marcel Dekker, Inc.	
	A399	SERGUEEV et al., "H-Phosphonate Approach for Solid-Phase Synthesis of Oligodeoxyribonucleoside Boranophosphates and Their Characterization," <u>J. Am. Chem. Soc.</u> , 1998, pp. 9417-9427, Vol. 120, American Chemical Society	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: June 8, 2009 (use as many sheets as necessary)				Application Number	09/506,011
				Filing Date	02/17/2000
				First Named Inventor	John Cooper Cox
				Art Unit	1648
				Examiner Name	Emily M. Le
Sheet	21	of	25	Attorney Docket Number	017227-0155

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ⁶
	A400	SMITH et al., "Pulmonary Deposition and Clearance of Aerosolized Alpha-1-Proteinase Inhibitor Administered to Dogs and to Sheep," <u>J. Clin. Invest.</u> , October 1989, pp. 1145-1154, Vol. 84			
	A401	STIRCHAK et al., "Uncharged stereoregular nucleic acid analogs: 2. Morpholino nucleoside oligomers with carbamate internucleoside linkages," <u>Nucleic Acids Research</u> , 1989, pp. 6129-6141, Vol. 17, No. 15			
	A402	STOTT et al., "Preliminary report: protection of cynomolgus macaques against simian immunodeficiency virus by fixed infected-cell vaccine," <u>The Lancet</u> , Dec. 22/29, 1990, pp. 1538-1541, Vol. 336			
	A403	SURI et al., "Non-cytolytic inhibition of hepatitis B virus replication in human hepatocytes," <u>Journal of Hepatology</u> , 2001, pp. 790-797, Vol. 35, Elsevier Science B.V.			
	A404	TARKOY et al., "31. Nucleic-Acid Analogues with Constraint Conformational Flexibility in the Sugar-Phosphate Backbone ('Bicyclo-DNA')," <u>Helvetica Chimica Acta</u> , 1993, pp. 481-510, Vol. 76			
	A405	TOKUNAGA et al., "Antitumor Activity of Deoxyribonucleic Acid Fraction From <i>Mycobacterium bovis</i> BCG. I. Isolation, Physicochemical Characterization, and Antitumor Activity," <u>JNCI</u> , April 1984, pp. 955-962, Vol. 72, No. 4			
	A406	TOKUNAGA et al., "A Synthetic Single-Stranded DNA, Poly(dG,dC), Induces Interferon- α/β and $-\gamma$, Augments Natural Killer Activity, and Suppresses Tumor Growth," <u>Jpn. J. Cancer Res.</u> , June 1988, pp. 682-686, Vol. 79			
	A407	UHLMANN et al., "Chapter 16. Oligonucleotide Analogs Containing Dephospho-Internucleoside Linkages," <u>Methods in Molecular Biology</u> , Vol. 20: Protocols for Oligonucleotides and Analogs, 1993, pp. 355-389, Humana Press Inc.			
	A408	UHLMANN et al., "Antisense Oligonucleotides: A New Therapeutic Principle," <u>Chemical Reviews</u> , June 1990, pp. 544-584, Vol. 90, No. 4			
	A409	BULOW, "Infectious Anemia," <u>Diseases of Poultry</u> , 9 th Edition, 1991, pp. 690-699			
	A410	VANDENDRIESSCHE et al., "Acyclic Oligonucleotides: Possibilities and Limitations," <u>Tetrahedron</u> , 1993, pp. 7223-7238, Vol. 49, No. 33, Pergamon Press Ltd., Great Britain			

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: June 8, 2009 (use as many sheets as necessary)		Complete if Known	
		Application Number Filing Date First Named Inventor Art Unit Examiner Name Attorney Docket Number	09/506,011 02/17/2000 John Cooper Cox 1648 Emily M. Le 017227-0155
Sheet	22	of	25

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A411	VERMA et al., "Modified Oligonucleotides: Synthesis and Strategy for Users," <u>Annu. Rev. Biochem.</u> , 1998, pp. 99-134, Vol. 67, Annual Reviews	
	A412	WAGNER et al., "Potent and selective inhibition of gene expression by an antisense heptanucleotide," <u>Nature Biotechnology</u> , July 1996, pp. 840-844, Vol. 14	
	A413	YAMAMOTO et al., "Pathogenesis of experimentally induced feline immunodeficiency virus infection in cats," <u>Am. J. Vet. Res.</u> , August 1988, pp. 1246-1258, Vol. 49, No. 8	
	A414	YAMAMOTO et al., "Feline Immunodeficiency Syndrome – A Comparison between Feline T-Lymphotropic Lentivirus and Feline Leukemia Virus," <u>Leukemia</u> , December 1988, pp. 204S-215S, Vol. 2, No. 12 Supplement	
	A415	YAMAMOTO et al., "Unique Palindromic Sequences in Synthetic Oligonucleotides are Required to Induce INF and Augment INF-Mediated Natural Killer Activity," <u>The Journal of Immunology</u> , June 15, 1992, pp. 4072-4076, Vol. 148, No. 12	
	A416	YUASA et al., "Isolation and Some Characteristics of an Agent Inducing Anemia in Chicks," <u>Avian Diseases</u> , April – June 1979, pp. 366-385, Vol. 23, No. 2	
	A417	YUASA et al., "Effect of Infectious Bursal Disease Virus Infection on Incidence of Anemia by Chick Anemia Agent," <u>Avian Diseases</u> , January – March 1980, pp. 202-209, Vol. 24, No. 1	
	A418	Cebon et al., <u>Proc. Am. Soc. Clin. Oncol.</u> , Vol. 21, 2002, page 86 (abstract)	
	A419	Supplemental European Search Report for European (EPO) Application No. 04 78 9341 mailed on November 5, 2007, together with forms EPO Form 2901 and EPO PTO form 1507.4.	
	A420	BUSSON, Marc et al., "Prediction of CD4+ T Cell Epitopes Restricted to HLA-DP4 Molecules", <u>Journal of Immunological Method</u> , December 2006, vol. 317, no. 1-2, pp. 144-151- XP002428277.	
	A421	CHEN, Qiyuan et al., "Immunodominant CD4+ Responses Identified in a Patient Vaccinated with Full-Length NY-ESO-1 Formulated with ISCOMATRIX Adjuvant", <u>Proceedings of the National Academy of Sciences of the United States of America</u> , 22 June 2004, vol. 101, no. 25, pp. 9363-9368, XP-002428274.	
	A422	JACKSON, Heather et al., "Striking Immunodominance Hierarchy of Naturally Occurring CD8+ and CD4+ T Cell Responses of Tumor Antigen NY-ESO-1", <u>Journal of Immunology</u> , 2006, May 2006, vol. 176, no. 10, pp. 5908-5917-XP002428276.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: June 8, 2009 (use as many sheets as necessary)				Complete if Known	
				Application Number	09/506,011
				Filing Date	02/17/2000
				First Named Inventor	John Cooper Cox
				Art Unit	1648
				Examiner Name	Emily M. Le
				Attorney Docket Number	017227-0155
Sheet	23	of	25		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A423	MANDIC, Maja et al., "One NY-ESO-1-Derived Epitope that Promiscuously Binds to Multiple HLA-DR and HLA-DP4 Molecules and Stimulates Autologous CD4+ T Cells from Patients with NY-ESO-1-Expressing Melanoma", <i>Journal of Immunology</i> , February 2005, vol. 174, no. 3, pp. 1751-1759-XP002428278.	
	A424	VALMORI, Danla et la. "Epitope Clustering in Regions Undergoing Efficient Proteasomal Processing Defines Immunodominant CTL Regions of a Tumor Antigen", <i>Clinical Immunology</i> , vol. 122, no. 2, February 2007, pp. 163-172, XP-002428275.	
	A425	BRETT et al., 1993, "Influence of the antigen delivery system on immunoglobulin isotype selection and cytokine production in response to influenza A nucleoprotein," <i>Immunology</i> , 80(2):306-12.	
	A426	BRITT et al., 1995, "Formulation of an immunogenic human cytomegalovirus vaccine: responses in mice," <i>J. Infect. Dis.</i> , 171(1): 18-25.	
	A427	BOMFORD et al., 1992, "The control of the antibody isotype response to recombinant human immunodeficiency virus gp120 antigen by adjuvants," <i>AIDS Res. Hum. Retroviruses</i> , (10): 1765-71.	
	A428	HELLING et al., 1995, "GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21," <i>Cancer Res.</i> , 55(13):2783-8.	
	A429	KANDIMALLA et al., 2001, "Effect of chemical modifications of cytosine and guanine in a CpG-motif of oligonucleotides: structure-immunostimulatory activity relationships," <i>Bioorg. Med. Chem.</i> , 9(3):807-13.	
	A430	KELER et al., 2000, "Differential effect of cytokine treatment on Fc alpha receptor I- and Fc gamma receptor I- mediated tumor cytotoxicity by monocyte-derived macrophages," <i>J. Immunol.</i> , 64(11):5746-52.	
	A431	KENSIL et al., 1991, "Development of a genetically engineered vaccine against feline leukemia virus infection," <i>J. Am. Vet. Assoc.</i> 199(10): 1423-7.	
	A432	KENSIL et al., 1993, "Adjuvant activity of QS-21 isomers," <i>Ann. N.Y. Acad. Sci.</i> , 690:392-5.	
	A433	LEWIS et al., 2000, "Evaluation of CD8(+) T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide," <i>Int. J. Cancer</i> , 87(3):391-8.	
	A434	LIVINSTON et al., 1995, "Impact of Immunological Adjuvants and Administration Route on HAMA Response after Immunization with Murine Monoclonal Antibody MELIMMUNE-1 in Melanoma Patients," <i>Vaccine Research</i> , 4(2):87-94.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: June 8, 2009 <i>(use as many sheets as necessary)</i>		Application Number	09/506,011
		Filing Date	02/17/2000
		First Named Inventor	John Cooper Cox
		Art Unit	1648
		Examiner Name	Emily M. Le
Sheet	24	of	25
		Attorney Docket Number	017227-0155

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A435	MARCIANI et al., 2000, "Development of semisynthetic Triterpenoid saponin derivatives with immune stimulating activity," <i>Vaccine</i> , 18(27): 3141-51.	
	A436	NEWMAN et al., 1994, "Induction of antigen-specific killer T Lymphocyte response using subunit SIVmac251 gag and env vaccines containing QS-21 saponin adjuvant," <i>AIDS Res. Hum. Retroviruses</i> , (7):853-61.	
	A437	WOOLRIDGE et al., 1997, "Immunostimulatory Oligodeoxynucleotides Containing CpG Motifs Enhance the Efficacy of Monoclonal Antibody Thereapy of Lymphoma," <i>Blood</i> , 89:2994-2998.	
	A438	Office Action issued 05/08/2009 by the Examiner in US application no. 10/622,470 (US 2004/0191270).	
	A439	Office Action issued 09/02/2008 by the Examiner in US application no. 10/622,470 (US 2004/0191270).	
	A440	Office Action issued 12/14/2007 by the Examiner in US application no. 10/622,470 (US 2004/0191270).	
	A441	Office Action issued 06/06/2007 by the Examiner in US application no. 10/622,470 (US 2004/0191270).	
	A442	Office Action issued 09/29/2006 by the Examiner in US application no. 10/622,470 (US 2004/0191270).	
	A443	Office Action issued 01/17/2006 by the Examiner in US application no. 10/622,470 (US 2004/0191270).	
	A444	Office Action issued 09/08/2005 by the Examiner in US application no. 10/622,470 (US 2004/0191270).	
	A445	Office Action issued 03/24/2005 by the Examiner in US application no. 10/622,470 (US 2004/0191270).	
	A446	Office Action issued 09/16/2008 by the Examiner in US application no. 11/183,187 (US 2006/0287263).	
	A447	Advisory Action issued 10/15/2007 by the Examiner in US application no. 11/183,187 (US 2006/0287263).	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: June 8, 2009 <i>(use as many sheets as necessary)</i>		Application Number	09/506,011
		Filing Date	02/17/2000
		First Named Inventor	John Cooper Cox
		Art Unit	1648
		Examiner Name	Emily M. Le
Sheet	25	of	25
		Attorney Docket Number	017227-0155

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A448	Office Action issued 07/25/2007 by the Examiner in US application no. 11/183,187 (US 2006/0287263).	
	A449	Office Action issued 03/07/2007 by the Examiner in US application no. 11/183,187 (US 2006/0287263).	
	A450	Office Action issued 08/25/2006 by the Examiner in US application no. 11/183,187 (US 2006/0287263).	
	A451	Office Action issued 02/23/2009 by the Examiner in US application no. 10/573,753 (US 2007/0190072).	
	A452	Office Action issued 04/22/2009 by the Examiner in US application no. 10/499,890 (US 2006/0210555).	
	A453	Office Action issued 12/31/2008 by the Examiner in US application no. 10/499,890 (US 2006/0210555).	
	A454	Office Action issued 05/12/2008 by the Examiner in US application no. 10/499,890 (US 2006/0210555).	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

U.S. Patent

" "

4,372,945

4,474,757